Cargando…

MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhang, Chunxiang
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768992/
https://www.ncbi.nlm.nih.gov/pubmed/19744308
http://dx.doi.org/10.1186/gm85
_version_ 1782173537270759424
author Zhang, Chunxiang
author_facet Zhang, Chunxiang
author_sort Zhang, Chunxiang
collection PubMed
description MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs), and its expression is significantly downregulated in dediffer-entiated VSMCs and atherosclerotic arteries. miR-145 plays a critical role in modulating VSMC phenotype. Because phenotypic modulation of VSMCs is an initial cellular event in the development of atherosclerosis, miRNAs, and miR-145 in particular, may represent new therapeutic targets for atherosclerosis.
format Text
id pubmed-2768992
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27689922010-09-09 MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? Zhang, Chunxiang Genome Med Minireview MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs), and its expression is significantly downregulated in dediffer-entiated VSMCs and atherosclerotic arteries. miR-145 plays a critical role in modulating VSMC phenotype. Because phenotypic modulation of VSMCs is an initial cellular event in the development of atherosclerosis, miRNAs, and miR-145 in particular, may represent new therapeutic targets for atherosclerosis. BioMed Central 2009-09-09 /pmc/articles/PMC2768992/ /pubmed/19744308 http://dx.doi.org/10.1186/gm85 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Minireview
Zhang, Chunxiang
MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title_full MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title_fullStr MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title_full_unstemmed MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title_short MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
title_sort microrna and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768992/
https://www.ncbi.nlm.nih.gov/pubmed/19744308
http://dx.doi.org/10.1186/gm85
work_keys_str_mv AT zhangchunxiang micrornaandvascularsmoothmusclecellphenotypenewtherapyforatherosclerosis